ImmunityBio Shares Rally as Anktiva Revenue Soars 700% to $38M
ImmunityBio shares jumped over 15% after Q4 revenue climbed 700% to $38.3 million, fueled by a 750% surge in Anktiva sales. The bladder cancer drug now holds approvals in 33 countries and is backed by new European and Middle East partnerships ahead of supplemental BLA filings.
1. Revenue Surge in Q4
ImmunityBio reported fourth-quarter revenue of $38.29 million, up 700% from $7.56 million a year earlier, driven by a 750% increase in Anktiva unit sales. This performance significantly surpassed consensus estimates of $37.02 million.
2. Expanded Global Approvals
Anktiva has secured regulatory approvals in 33 countries for non-muscle invasive bladder cancer after initial FDA clearance in 2024. The company also formed new distribution partnerships in Europe and the Middle East, including deployment of an 85-person sales team.
3. Share Performance and Technical Indicators
Shares of ImmunityBio climbed over 15% intraday, extending a 55% gain over the past month. The stock trades above its 20-day and 100-day simple moving averages, signaling strong momentum despite neutral RSI readings.
4. Future Clinical and Regulatory Plans
ImmunityBio plans to submit supplemental biologics license application data following a Type B end-of-phase meeting for Anktiva’s expanded papillary NMIBC indication. Ongoing clinical trials aim to broaden Anktiva’s immunotherapy platform across multiple cancer types.